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BACKGROUND/PURPOSE: Non-Hodgkin’s lymphoma (NHL) is the second most common acquired 
immunodeficiency syndrome-defining malignancy with a high mortality rate. This study aimed to de-
scribe changes in the incidence and clinical characteristics of NHL in human immunodeficiency virus 
(HIV)-infected patients in a referral hospital for HIV care.
METHODS: The medical records of HIV-infected patients diagnosed with NHL between June 1994 and 
December 2006 were retrospectively reviewed. Risk stratification of each patient was evaluated using the 
International Prognostic Index (IPI). Case patients were followed at least for 2 years to assess the 2-year 
survival rates.
RESULTS: During the 12-year period, 38 HIV-infected patients were diagnosed with NHL. Their median 
cluster of differentiation 4 count was 82 cells/μL (range, 2–477 cells/μL) at diagnosis. Before the introduc-
tion of highly active antiretroviral therapy (HAART) in April 1997, 9/175 HIV-infected patients (5.1%) de-
veloped NHL compared with 29/1,386 patients (2.1%) in the HAART era (p < 0.05). Although the 2-year 
survival rate did not differ significantly between patients diagnosed in the pre-HAART era (22.2%) and 
those diagnosed in the HAART era (24.1%), patients receiving HAART for more than 6 months had better 
survival rates (p < 0.05). A low IPI score was a good prognostic factor predictive of a patient’s outcome.
CONCLUSION: The incidence of NHL in HIV-infected patients declined significantly in the HAART era. 
Despite the introduction of HAART, the short-term survival of the patients with NHL remained poor. 
The IPI was a good predictor for survival.
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Introduction
Kaposi’s sarcoma and non-Hodgkin’s lymphoma (NHL) 
are the most common malignancies in human immuno-
deficiency virus (HIV)-infected patients.1 After recogni-
tion of acquired immunodeficiency syndrome (AIDS) and 
HIV infection, it has been noted that the incidence of 
both NHL and Hodgkin’s lymphoma is much higher in 
HIV-infected patients than in the general population.2–4 
In a review of the cancer registries of 11 regions in the 
United States (Surveillance Epidemiology and End Results 
Program), the incidence of NHL increased from 10.4/
100,000 in 1973 (before the onset of the AIDS epidemic) 
to 21.1/100,000 in 1995.5 Therefore, NHL has been de-
fined as an AIDS-defining illnesses, in addition to primary 
central nervous system (CNS) lymphoma, since 1985.6
The risk factors for HIV-associated NHL are not well 
understood, but the absolute risk increases with age and is 
higher in men and in whites.7 Although the incidence of 
HIV-associated NHL has decreased and the survival of the 
patients with HIV-associated NHL has been improved after 
highly active antiretroviral therapy (HAART) was intro-
duced, NHL is still a prominent malignancy in patients 
with AIDS.8–12
In Taiwan, the mortality of HIV-infected patients has de-
clined significantly in the HAART era, and non-AIDS-related 
conditions are now increasingly recognized as causes of 
death.13 However, there are few reports on the characteristics 
of NHL in HIV-infected patients in Taiwan. In this study, 
we aimed to describe the change in the incidence and clin-
ical characteristics of NHL in patients with HIV infection 
enrolled in an observational study at a referral hospital 
for HIV care in Taiwan.
Methods
Ethics
This study was approved by the Institutional Review 
Board of the National Taiwan University Hospital and the 
need for informed consent was waived.
Study population
A total of 1,561 non-hemophiliac HIV-infected persons 
aged 15 years or older, who received medical care between 
June 1994 and December 2006, were enrolled in an 
prospective observational study at the National Taiwan 
University Hospital, the largest referral hospital for inpa-
tient and outpatient care in Taiwan.14 The date of enroll-
ment was defined as the date of the first visit at which the 
patient sought HIV care at the hospital. A computerized 
case report form was used to record patient demograph-
ics, risk factors for HIV-infection, cluster of differentia-
tion 4 (CD4) and CD8 lymphocyte counts, plasma HIV 
RNA load, HIV-related opportunistic illnesses (including 
opportunistic infections and malignancies), prescribed 
antiretroviral therapy (including HAART), therapy for 
malignancy and outcomes. Patients were divided into two 
groups based on the date of enrollment: from June 1994 
to March 31, 1997 (pre-HAART) and from April 1, 1997 to 
December 31, 2006 (post-HAART). The study ended on 
December 31, 2008.
Diagnostic investigations
During the 12-year study period, all the patients received 
stepwise investigations described previously as routine 
clinical care practices to identify the etiology of any pre-
senting symptoms and signs.15 For patients who presented 
with lymphadenopathy or mucocutaneous lesions, biopsy 
was performed if necessary. For visceral lesions, which re-
mained unknown after serial non-invasive diagnostic 
tests, sonography, computed tomography or endoscopy-
guided aspiration and biopsy (for those lesions that were 
accessible) were performed. Also, microbial cultures in-
cluding cultures for bacteria, fungi, mycobacteria, and 
viruses were performed (especially for febrile patients).
Definitions
NHL was defined as definite if the lesions were diagnosed 
by histopathology. Probable cases were defined as those 
lesions with characteristic appearance, plus compatible 
clinical findings and exclusion of other possible infectious 
diseases, and a favorable response to specific therapy for 
NHL, e.g. systemic chemotherapy or radiotherapy.
Each patient was evaluated using the International 
Prognostic Index (IPI), which was established in 1993 
by the International Non-Hodgkin’s Lymphoma Prog-
nostic Project. The IPI criteria are: (1) age > 60 years; (2) 
serum lactate dehydrogenase concentration above nor-
mal; (3) Eastern Cooperative Oncology Group Perfor-
mance Status Scale ≥ 2; (4) Ann Arbor stage III or IV; and 
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(5) more than one extra-nodal disease site.16 Each factor 
counts as one score and the risk is stratified according to 
the sum of scores: low risk = 0–1; low-intermediate risk = 2; 
high-intermediate risk = 3; high risk = 4–5. The stratified 
risk group was associated with different 5-year survival 
rates.
Statistical analysis
All statistical analyses were performed using SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA). Categorical variables 
were compared by Fisher’s exact test or χ2 test. Non-
categorical variables were compared using the Mann-
Whitney U test. All comparisons were two-tailed and a 
p value < 0.05 was considered statistically significant.
Results
From June 1994 to December 2006, 1,561 HIV-infected 
patients were enrolled. Their median CD4 count at base-
line was 110 cells/μL and 56.1% had a baseline CD4 count 
< 200 cells/μL. The major route of HIV transmission was 
sexual contact. Malignancy was documented in 7.8% (121/
1,561) of the enrolled patients. Kaposi’s sarcoma was the 
most common (67/1,561; 4.3%) followed by NHL (38/
1,561; 2.4%). The 38 patients with NHL comprised the 
study population in the present study, and their demo-
graphics and clinical characteristics are shown in Table 1.
Most of the patients were heterosexuals (55.3%). At the 
time of NHL diagnosis, the median age of the patients was 
39.9 years (range, 22.5–66.9 years), 71.1% (27/38) had a CD4 
cell count < 200 cells/μL, and 76.3% (29/38) were naïve to 
antiretroviral therapy. The median CD4 count and plasma 
HIV RNA load were 82 cells/μL (range, 2–477 cells/μL) 
and 5.32 log10 copies/mL (range, 1.70–5.88 log10 copies/
mL), respectively (Table 1). Five patients (13.2%) also had 
other concurrent malignancies, including Kaposi’s sarcoma 
(4 patients) and hepatocellular carcinoma (1 patient).
The diagnosis was definite in 35 patients (92.1%) and 
probable in three patients (7.9%). All three probable cases 
were primary CNS lymphomas. The most common his-
topathology of NHL was diffuse large B cell lymphoma 
(57.9%), followed by Burkitt’s lymphoma (18.4%), and 
primary CNS lymphoma (13.2%; Table 1). Nearly 85% 
of NHL cases presented with extra-nodal involvement. In 
those patients, the CNS was the most commonly involved 
extra-nodal site (pre-HAART era, 33.3%; HAART era, 
51.7%). Visceral organ involvement was seen in about 20% 
of patients (pre-HAART era, 22.2%; HAART era, 20.7%), 
most commonly involving the gastrointestinal tract.
Table 1. Demographics of human immunodeficiency virus-
infected patients with non-Hodgkin lymphoma (n = 38)
Baseline data
Sex, male 35 (92.1)
HIV risk factor
 MSM 15 (39.5)
 Heterosexual 21 (55.3)
 Others 2 (5.2)
Data at enrollment of cohort
 CD4 count (cells/uL) 43 (2–571)
 CD8 count (cells/uL) 580 (56–2,957)
 PVL (log10/mL) 5.56 (2.60–5.87)
Data at diagnosis of 
HIV-associated lymphoma
 Definite cases 35 (92.1)
 Probable cases 3 (7.9)
 Extra-nodal involvement 33 (84.6)
 Concurrent opportunistic infection 21 (55.3)
 Concurrent malignancy 5 (13.2)
 Age (yr) 39.9 (22.5–66.9)
 Antiretroviral-naïve 29 (76.3)
 Prior AIDS 29 (76.3)
 CD4 count (cells/μL) 82 (2–477)
 PVL (log10/mL) 5.32 (1.70–5.88)
Episodes categorized by CD4 count
 < 200 cells/μL  27 (71.0)
 200–350 cells/μL 6 (15.8)
 > 350 cells/μL 5 (13.2)
Outcome
 2-year survival 9 (23.7)
Histopathology
 Burkitt’s lymphoma 7 (18.4)
 Primary CNS lymphoma  5 (13.2)
 DLBCL  22 (57.9)
 Others 4 (10.5)
MSM = Men who have sex with men; CD4 = cluster of differentiation; 
PVL = plasma HIV RNA load; HIV = human immunodeficiency 
virus; CNS = central nervous system; DLBCL = diffuse large B-cell 
lymphoma.
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The crude incidence of NHL declined significantly after 
the introduction of HAART; A total of 9/175 patients 
(5.1%) developed NHL in the pre-HAART era compared 
with 29/1,386 patients (2.1%) in the HAART era (p < 0.05; 
Table 2). Patients in the HAART era were more likely to be 
homosexual males (48.2%) than those in the pre-HAART 
era (11.1%; p = 0.06). There were no significant differences 
in CD4 cell counts, prior AIDS status, being naïve to anti-
retroviral therapy, concurrent opportunistic infections or 
malignancy, and stage III/IV disease between patients 
enrolled in the pre-HAART and HAART eras.
Despite the introduction of HAART and improving 
chemotherapeutic regimens for NHL, 2-year cumulative 
survival remained poor: 22.2% in the pre-HAART and 
24.1% in the HAART era (p = 0.99; Table 2). Figure 1 shows 
the Kaplan-Meier survival curve for 2-year survival in the 
pre-HAART and post-HAART eras. Nearly 40% of the pa-
tients died before receiving chemotherapy (44.4% in the 
pre-HAART era; 37.9% in the post-HAART era). Figure 2 
shows 2-year Kaplan-Meier survival curves for patients 
given HAART for more than 6 months and for those given 
HAART for less than 6 months. Patients given HAART for 
more than 6 months had a better survival rate (log-rank 
test, p = 0.001).
A low IPI score was associated with better survival 
(p < 0.05; Table 3). Other factors that tended to be associ-
ated with improved outcome, but were not statistically 
significant due to the small sample size, included CD4 
count > 200 cells/μL, initiation time of HAART, HAART 
combined with chemotherapy or radiotherapy, stage 
III/IV disease, and a lower lactate dehydrogenase level 
(Table 3). Exclusion of the three probable cases of primary 
CNS lymphoma did not alter the results.
Of the nine patients with 2-year survival after the ini-
tial diagnosis of NHL, only one was lost to follow-up 30 
months later. The remaining eight patients received regular 
follow-up at clinics and showed no evidence of recurrence.
Table 2. Incidence rate and other data at diagnosis of human immunodeficiency virus-associated non-Hodgkin’s lymphoma 
according to treatment eraa
 Pre-HAART era (n = 9) HAART era (n = 29) p
Proportion of HIV-associated lymphoma (%) 5.1 2.1 < 0.05
MSM 1 (11.1) 14 (48.2) 0.06
CD4 count (cells/μL) 97 (3–477) 82 (2–453) 0.83
PVL (log10/mL) – 5.31 (1.70–5.88) –
Previous AIDS 7 (77.8) 22 (75.9) 1.00
Antiretroviral-naïve 6 (66.7) 23 (79.3) 0.66
NHL as presenting disease 5 (55.6) 14 (48.3) 1.00
Concurrent opportunistic infection 4 (44.4) 17 (58.6) 0.70
Concurrent malignancy 2 (22.2) 3 (10.3) 0.57
Stage III/IV disease 7 (77.8) 23 (79.3) 1.00
2-year survival 2 (22.2) 7 (24.1) 1.00
aData presented as %, n (%) or median (range). MSM = Men who have sex with men; HIV = human immunodeficiency virus; CD4 = cluster of 
differentiation 4; PVL = plasma HIV RNA load; AIDS = acute immunodeficiency diseases; NHL = non-Hodgkin’s lymphoma.
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Figure 1. Kaplan-Meier survival plot showing 2-year cumulative 
survival rates in the pre-highly active antiretroviral therapy (from 
June 1994 to March 1997) and highly active antiretroviral ther-
apy eras (from April 1997 to December 2006). HAART = Highly 
active antiretroviral therapy.
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Discussion
In this study, we found that NHL remains an important 
HIV-associated malignancy (38/121; 31.4%), though it 
was not a common AIDS-defined illness (38/1,561; 2.4%). 
Similar to other opportunistic illnesses,17 the proportion 
of our patients diagnosed with NHL declined significantly 
from 5.1% in the pre-HAART era to 2.1% in the HAART 
era, which can be attributed to the enrollment of patients 
during the earlier stages of HIV infection and to the intro-
duction of HAART. However, NHL and other opportunis-
tic illnesses continue to occur in HIV-infected patients 
with depleted CD4 cell counts. Table 2 shows that more 
than 70% of patients in both the pre-HAART (77.8%) and 
HAART eras (75.9%) also had AIDS, or had been diag-
nosed with AIDS before NHL. Also, a high proportion of 
patients either had concurrent opportunistic infections 
(44.4% and 58.6% in the pre-HAART and post-HAART eras, 
respectively) or were naïve to anti retroviral therapy before 
NHL diagnosis (66.7% and 79.3% in the pre-HAART and 
post-HAART eras, respectively). These findings suggest 
that the importance of early diagnosis of HIV infection, 
and the continued improvement and promotion of access 
to HIV testing and care (including HAART) cannot be 
overemphasized.17–19
Although the incidence of HIV-associated NHL de-
clines, characteristics such as stage at presentation, bone 
marrow infiltration or performance status did not differ 
in a study comparing 99 patients diagnosed prior to 1996 
with 55 patients diagnosed from 1996 to 1999.20 Systemic 
AIDS-related lymphomas show a number of differences 
from NHL in non-HIV-infected patients, including B symp-
toms and advanced stage disease, extra-nodal involvement, 
Table 3. Factors associated with 2-year survival of human immunodeficiency virus-associated non-Hodgkin’s lymphoma
 Survived (n = 9) Died (n = 29) p
Age (yr) 34.6 (33.5–39.8) 37.6 (33.8–38.3) 0.13
CD4 > 200 cells/μL 4 (44.4) 23 (79.3) 0.09
HIV PVL (log10/mL) 4.37 ± 1.60 4.59 ± 1.47 0.58
Concurrent opportunistic infection 3 (33.3) 18 (62.1) 0.25
Concurrent malignancy 0 (0) 5 (17.2) 0.31
Receipt of C/T and/or R/T 9 (100) 14 (48.3) < 0.05
HAART initiated 9 (100) 19 (65.6) 0.08
HAART concomitantly with C/T or R/T 4 (44.4) 8 (27.6) 0.42
Deferred 5 (55.5) 2 (6.9)
Prior AIDS status 5 (55.6) 24 (82.8) 0.17
Stage III/IV disease 5 (55.6) 25 (86.2) 0.07
International prognostic index 1.67 ± 0.87 2.85 ± 0.77 < 0.05
lactate dehydrogenase (U/L) 467 (445–833) 1,281 (626–4,727) 0.06
aData presented as n (%), median (interquartile range) or mean ± standard deviation. CD4 = cluster of differentiation 4; HIV = human immu-
nodeficiency virus; PVL = plasma HIV RNA load; C/T = chemotherapy; R/T = radiotherapy; HAART = highly active antiretroviral therapy; 
AIDS = acute immunodeficiency diseases.
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Figure 2. Kaplan-Meier survival plot showing 2-year cumulative 
survival rates of patients given highly active antiretroviral therapy 
for ≥ 6 months or < 6 months in the HAART era. HAART = Highly 
active antiretroviral therapy.
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plasmacellular differentiation, and association with 
Epstein-Barr virus.21 Extra-nodal involvement may be 
found at unusual sites, including the lung, oral cavity, vis-
ceral organs and CNS.1 In this study, a high proportion of 
extra-nodal involvement was noted (84.6%) and the most 
common site was the CNS (47.4%), followed by bone mar-
row (26.3%), mucocutaneous sites, including skin and 
gingival (23.7%), and visceral organs (21.1%).
The survival of patients with HIV-associated NHL was 
poor in the pre-HAART era, but improved with introduction 
of HAART and the institution of chemotherapy at higher 
doses using improved treatment modalities. Biggar et al 
found that the 2-year survival rate of patients with NHL 
in New York city significantly improved from 1980 to 
2000, increasing from 15% to 41% (p < 0.0001).22 Another 
prospective observational study showed that 2-year sur-
vival rates improved from 29.0% in the pre-HAART era to 
41.0% in the HAART era (p = 0.12; the lack of significance 
was probably due to inadequate sample size).20 In this 
study, we did not see an improvement in 2-year survival 
rates in the HAART era. The most likely explanation for 
this is immunosuppression and a delay in NHL diagnosis. 
Nearly 40% of the patients died before chemotherapy or 
radiotherapy could be instituted. The median CD4 count 
in our HAART era patients (82 cells/μL; range, 2–453 cells/
μL) was as low as that in the pre-HAART era patients 
(97 cells/μL; range, 3–477 cells/μL).
HAART, in combination with chemotherapy, is also 
important in the modern era for improved survival of pa-
tients with HIV-associated lymphomas.23 However, our 
study did not show improved outcomes for patients re-
ceiving HAART in combined with chemotherapy or radio-
therapy, but this may be attributable to the small sample 
size of this study. HAART therapy for more than 6 months 
was associated with a better outcome, suggesting that 
HAART given for a longer period of time restores immunity 
and prevents the relapse of lymphomas.24
There are several studies that predict the outcomes of 
HIV-associated NHL. Lim et al reported that IPI, which is 
a well established prognostic index for immunocompe-
tent patients with intermediate-grade lymphoma, is also 
a good predictor of outcome in HIV-associated lympho-
mas.25 Another study by Bower et al found that low, or 
low-intermediate IPI scores and CD4 cell counts of > 100 
cells/μL were also good predictive factors.26 Our study 
only supports IPI as a good predictive factor (the CD4 cell 
count was not statistically significant). This may also be 
due to the small sample size used in this study.
In conclusion, our findings suggest that the incidence 
of HIV-associated NHL significantly declined during the 
HAART era, although it still occurred in patients with ad-
vanced HIV infection. Despite the introduction of HAART, 
the short-term survival rate of patients with NHL remains 
poor, although the IPI is a good predictor for survival.
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